Foro de culturismo, musculación, pesas, fitness y esteroides anabólicos

valen23 escribió:Buenas malaga!

Yo voy hacer tu ciclo pero con arimidex en vez de tamoxi y provi, tengo una duda: el arimidex lo pondre de la semana uno hasta el ultimo pincho de hcg ¿es correcto? despues empezare con clomifeno y tamoxifeno... Estoy en lo cierto?

Gracias de antemano...

strong escribió:hola malaga se podria cambiar el susta por testoviron

elsasuiza escribió:con ese ciclo de cuanto seran las ganancias aproximadas, tanto de masa como fuerza? masa magra o muxa retencion¿

valen23 escribió:Ok, malaga, yo lo metere desde la una porque quiero hacer un kick star con dianabol, preguntaba eso porque en el prospecto de arimidex pone no usar con tamoxifeno... tengo entendido k una quita el poder del otro. por eso habia pensao de no ponerlo... cuando acabe con hcg acabar con ari, y empezar con tamoxi y clomifeno, pero vaya k me fio de lo k dices.

elsasuiza escribió:con ese ciclo de cuanto seran las ganancias aproximadas, tanto de masa como fuerza? masa magra o muxa retencion¿

FLFH escribió:Efectivamente, el tamoxifeno ANULA el efecto del arimidex... Usa durante el ciclo arimidex y deja el tamoxifeno para el PCT

elsasuiza escribió:con ese ciclo de cuanto seran las ganancias aproximadas, tanto de masa como fuerza? masa magra o muxa retencion¿

Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex™ and Tamoxifen Alone or in Combination' (ATAC) trial


Abstract

The ATAC trial evaluates in a randomized, double-blind design, Arimidex™ (anastrozole) alone or in combination with tamoxifen, relative to tamoxifen alone as 5-year adjuvant treatment in postmenopausal women with early breast cancer. Patients included in the pharmacokinetic (PK) sub-protocol had been in ATAC for greater than or equal to3 months, taking their medication in the morning and were 100% compliant for the preceding 14 days. Blood samples were collected 24 plusminus 4 h after last dose. Trough (Cmin) plasma concentrations of anastrozole, tamoxifen and desmethyltamoxifen (DMT) were measured by validated methods. The PK results were based on a total of 347 patients (131 anastrozole (1 mg o.d.), 111 tamoxifen (20 mg o.d.), 105 anastrozole and tamoxifen (1 and 20 mg o.d. respectively)). The geometric mean steady-state trough plasma concentrations of tamoxifen and DMT were statistically equivalent in patients receiving tamoxifen alone or in combination with anastrozole: geometric mean tamoxifen = 94.8 ng ml–1and 95.3 ng ml–1in tamoxifen alone and combination groups, respectively; geometric mean DMT = 265.1 and 277.6 ng ml-1in the tamoxifen and anastrozole and tamoxifen groups, respectively. The geometric mean anastrozole levels were 27% lower (90% Cl 20–33%; P < 0.001) in the presence of tamoxifen than with anastrozole alone. Baseline plasma oestradiol levels were not obtained in the PK sub-protocol, however, such information was available from a similar ATAC sub-protocol, which evaluated bone mineral density. Mean oestradiol levels were 21.3, 19.3, and 21.6 pmol l-1prior to treatment and 3.7, 20.9 and 3.6 pmol l-1after 3 months in the anastrozole, tamoxifen, and combination groups, respectively (n = 167). On-treatment values were below the detection limit (3 pmol l-1) in 43.6 and 38.5% of the anastrozole alone and anastrozole in combination with tamoxifen groups, respectively. As a result of (a) the lack of effect of anastrozole on tamoxifen and DMT levels and (b) the observed fall in blood anastrozole levels having no significant effect on oestradiol suppression by anastrozole, we conclude that the observed reduction in anastrozole levels by tamoxifen is unlikely to be of clinical significance when anastrozole and tamoxifen are administered together. © 2001 Cancer Research Campaign